Treatment of latent tuberculosis infection.
Treatment of latent tuberculosis infection (LTBI) is considered an essential component of TB control programs in several industrialized countries and is being used in selected situations in developing countries. In 2000, the American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC) published new recommendations on the diagnosis and treatment of LTBI. These guidelines emphasized targeted tuberculin testing as a means of diagnosis in populations at risk, and expanded the choice of drug regimens to be used for treatment. After the implementation of the recommendations, unexpected and serious hepatic injury with the use of rifampin and pyrazinamide occurred, resulting in a modification of the recommendations. This article reviews the populations who should be considered for targeted tuberculin testing, scientific rationale for the selected treatment regimens, recently completed studies related to rifampin and pyrazinamide, and the prior and updated recommendations for treatment of LTBI.
Cohn
David L
DL
Denver Public Health and the Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO 80204, USA. dcohn@dhha.org
D000995:Antitubercular Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D011322:Primary Prevention / Q000379:methods; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014374:Tuberculin Test; D014376:Tuberculosis / Q000188:drug therapy* / Q000517:prevention & control*; D014481:United States
D000995:Antitubercular Agents; D001500:BCG Vaccine